GlassScriptPhysician profile
Todd Michael Erickson
NPI 1174671739
$7,216.52
in general payments reported to CMS, 2019-2025
27 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,182 · 2020: $345 · 2021: $143 · 2022: $946 · 2023: $2,498 · 2024: $530 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,220 · Food and Beverage: $1,338 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,220.00 |
| Food and Beverage | $1,338.29 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,279.56 | 2019-2025 | Imfinzi, Tagrisso, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,627.06 | 2019 | |
| Jazz Pharmaceuticals INC. | $311.58 | 2023-2025 | |
| Seagen INC. | $275.01 | 2019-2022 | |
| Amgen INC. | $215.58 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $163.99 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Rybrevant |
| Janssen Biotech, INC. | $142.15 | 2019-2022 | |
| Kyowa Kirin, INC. | $128.05 | 2024 | Poteligeo |
| Pfizer INC. | $111.52 | 2021-2024 | |
| Genentech USA, INC. | $109.84 | 2019 | |
| Genzyme Corporation | $105.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Abbvie INC. | $87.45 | 2022 | |
| Merck Sharp & Dohme LLC | $84.48 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $69.15 | 2019-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $43.84 | 2019-2020 | |
| Celgene Corporation | $42.89 | 2019-2024 | Reblozyl |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Eisai INC. | $23.98 | 2019 | |
| Secura Bio, INC. | $17.15 | 2019 | |
| Daiichi Sankyo INC. | $16.86 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2019 | |
| Clovis Oncology, INC. | $14.58 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.03 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.42 | 2019 | |
| Lilly USA, LLC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.